Enhancer of Zeste Homolog 2 Protein
"Enhancer of Zeste Homolog 2 Protein" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A histone-lysine N-methyltransferase and catalytic subunit of Polycomb Repressive Complex 2. It methylates LYSINE 9 (H3K9me) and LYSINE 27 (H3K27me) of HISTONE H3, leading to transcriptional repression of the affected target gene. EZH2 also methylates non-histone proteins such as GATA4 TRANSCRIPTION FACTOR and the nuclear receptor RORA. It regulates CIRCADIAN CLOCKS via histone methylation at the PROMOTER REGIONS of the circadian genes and its repressive activity is also important for the identity and differentiation of EMBRYONIC STEM CELLS.
| Descriptor ID |
D000071221
|
| MeSH Number(s) |
D05.500.781.750.250 D08.811.913.555.500.800.400.500.500 D12.776.660.235.600.200.250 D12.776.664.235.800.200.250 D12.776.930.780.890.200.250
|
| Concept/Terms |
Enhancer of Zeste Homolog 2 Protein- Enhancer of Zeste Homolog 2 Protein
- Lysine N-Methyltransferase-6
- Lysine N Methyltransferase 6
- Histone-Lysine N-Methyltransferase EZH2
- EZH2, Histone-Lysine N-Methyltransferase
- Histone Lysine N Methyltransferase EZH2
- Enhancer of Zeste Homolog 2
|
Below are MeSH descriptors whose meaning is more general than "Enhancer of Zeste Homolog 2 Protein".
Below are MeSH descriptors whose meaning is more specific than "Enhancer of Zeste Homolog 2 Protein".
This graph shows the total number of publications written about "Enhancer of Zeste Homolog 2 Protein" by people in this website by year, and whether "Enhancer of Zeste Homolog 2 Protein" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 0 | 2 | 2 |
| 2009 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 2 | 2 |
| 2012 | 0 | 1 | 1 |
| 2013 | 0 | 3 | 3 |
| 2014 | 0 | 2 | 2 |
| 2015 | 0 | 1 | 1 |
| 2016 | 4 | 0 | 4 |
| 2017 | 2 | 0 | 2 |
| 2018 | 1 | 1 | 2 |
| 2020 | 3 | 2 | 5 |
| 2021 | 1 | 0 | 1 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Enhancer of Zeste Homolog 2 Protein" by people in Profiles.
-
EZH2 activates Wnt/ß-catenin signaling in human uterine fibroids, which is inhibited by the natural compound methyl jasmonate. F S Sci. 2023 08; 4(3):239-256.
-
Immune activation is essential for the antitumor activity of EZH2 inhibition in urothelial carcinoma. Sci Adv. 2022 10 07; 8(40):eabo8043.
-
Therapeutic Targeting of EZH2 and BET BRD4 in Pediatric Rhabdoid Tumors. Mol Cancer Ther. 2022 05 04; 21(5):715-726.
-
SP1-induced long non-coding RNA SNHG6 facilitates the carcinogenesis of chondrosarcoma through inhibiting KLF6 by recruiting EZH2. Cell Death Dis. 2021 01 11; 12(1):59.
-
Clinicopathologic significance of protein lysine methyltransferases in cancer. Clin Epigenetics. 2020 10 13; 12(1):146.
-
Epigenetic Control of Cdkn2a.Arf Protects Tumor-Infiltrating Lymphocytes from Metabolic Exhaustion. Cancer Res. 2020 11 01; 80(21):4707-4719.
-
Antihistamine Drug Ebastine Inhibits Cancer Growth by Targeting Polycomb Group Protein EZH2. Mol Cancer Ther. 2020 10; 19(10):2023-2033.
-
Ezh2 Represses Transcription of Innate Lymphoid Genes in B Lymphocyte Progenitors and Maintains the B-2 Cell Fate. J Immunol. 2020 04 01; 204(7):1760-1769.
-
MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer. Nat Commun. 2020 01 17; 11(1):338.
-
Signaling function of PRC2 is essential for TCR-driven T cell responses. J Exp Med. 2018 04 02; 215(4):1101-1113.